Bacterial infection caused by *Bartonella henselae* is the most common cause of a benign regional lymphadenopathy known as 'cat scratch disease' (CSD) in children and young adults ([@bib45]). Affected people have frequently been in contact with cats. For example, in one study, cat contact was documented in 74% of 600 suspect cases ([@bib8]). The organism is also associated with bacillary angiomatosis and bacillary peliosis, two proliferative vascular disorders that may occur in humans infected with human immunodeficiency virus ([@bib7]). *Bartonella henselae* has been isolated from the blood of subclinically ill, seropositive cats and also from cats with a variety of clinical manifestations like fever, depression, anorexia, lethargy, lymphadenopathy, myalgia, uveitis, gingivitis ([@bib42], [@bib22]) and some cats have neurological dysfunction ([@bib15], [@bib33]). While most cats infected by *B henselae* never develop detectable clinical signs of disease, the spectrum of *B henselae* associated illnesses in diseased cats are similar to those observed in human patients with moderate to severe CSD ([@bib4], [@bib5], [@bib7]). *Bartonella* species seroprevalence in cats varies by region but is as high as 93% in some geographical areas of the United States ([@bib18], [@bib12], [@bib31]). The organism is transmitted between cats by fleas ([@bib6]) and *B henselae* DNA was amplified from 34.8% and 30.4% of cats and their fleas, respectively ([@bib21]). Thus, *B henselae* infection is most common in cats exposed to fleas.

Neurological complications of *B henselae* infection of people are rare. It has been estimated that only 2--3% of the estimated 24,000 human patients in the US who contract CSD annually develop neurological complications ([@bib4], [@bib5], [@bib17], [@bib24]). However, a human study that sought to identify the cause and characterize signs of encephalitis in California over a 2 year period found *Bartonella* species to be the most common bacterial agent associated with encephalitis ([@bib14]). Signs of neurological dysfunction include encephalopathy ([@bib4], [@bib5], [@bib24], [@bib30]), transverse myelopathy ([@bib35]), demyelinating polyneuropathy ([@bib26]), facial nerve paralysis ([@bib43]), aseptic meningitis ([@bib46]), cerebral arteritis ([@bib41]), neuroretinitis ([@bib32]) and radiculopathy ([@bib27]). Encephalopathy is considered one of the most serious complications of CSD ([@bib30], [@bib7]) and can manifest with fever, headaches, mentation changes (aggression, confusion and excitability), combative behavior, tonic-clonic seizures, status epilepticus and occasionally, coma that develops 1--8 weeks after the onset of lymphadenopathy ([@bib4], [@bib5], [@bib44]). Some studies have proposed that *B henselae* may have a role in the pathogenesis of acquired immunodeficiency syndrome (AIDS) encephalopathy ([@bib34], [@bib39], [@bib40]). The prognosis associated with CSD encephalopathy in immunocompetent patients is generally considered to be good with rare long term complications ([@bib4], [@bib5]).

Several studies have associated mild neurological dysfunction to *B henselae* infection of experimentally inoculated cats ([@bib19], [@bib33], [@bib28]) and *B henselae* can replicate in cells from the central nervous tissues of cats ([@bib29]). The neurological signs included exaggerated or diminished response to stimuli, aggressive behavior, focal seizures, nystagmus, and generalized tremors ([@bib19], [@bib33], [@bib28]). However, the role *B henselae* plays in neurological disease in client-owned cats is largely unknown. Similar neurological manifestations are common in client-owned cats for which a definitive diagnosis is unknown. The objective of this study was to compare *B henselae* antibody test results among groups of cats with and without clinical manifestations of neurological disease.

Material and methods {#sec2}
====================

Experimental design {#sec2.1}
-------------------

The records database in the Specialized Infectious Diseases Laboratory at Colorado State University was searched between January 2002 and May 2004 for feline serum sample submissions that listed neurological disease as a presenting complaint. All cases with adequate serum available for further testing were accepted (group 1). The submission paperwork was retrieved and each of the cats was further characterized by one of the authors (LP); the neurological complaints divided into seizures or other neurological signs. Two control groups were also selected. Group 2 consisted of sequentially selected, clinically ill cats for which adequate sample was available for additional testing, the presenting complaint was non-neurological, and the sample period encompassed at least a 1 year period. Group 3 consisted of sequentially selected, healthy cats for which adequate sample was available for additional testing, and the sample period encompassed at least a 1 year period. Age, breed, sex, and state were recorded for each case. Each sample had been previously submitted for infectious disease testing; *Toxoplasma gondii*, FeLV, FIV, and coronavirus were most common. Each sample had been stored at −20 °C or −80 °C until thawed and assayed in an IgG ELISA for the detection of antibodies against *B henselae* ([@bib22]). In this ELISA, a 1:64 dilution of positive control, negative control, and suspect sera are each assayed in quadruplicate wells and the mean absorbances calculated. The mean absorbance values were converted to %ELISA units by use of the following formula: (test sample mean absorbance minus the negative control sample mean absorbance)/(positive control sample mean absorbance minus the negative control sample mean absorbance) multiplied by 100. An individual cat was considered positive for *B henselae* antibodies if the %ELISA value was greater than the mean %ELISA value plus 3SD of the pre-inoculation samples for a group of 26 specific pathogen-free cats (10 kittens at 8 weeks of age and 16 cats at 3 years of age). Positive suspect serum sample results were converted to estimated titers ranging from 1:64 to 1:4096 by comparing to a standard curve.

Statistical evaluation {#sec2.2}
----------------------

Whether or not the cats in this study had been exposed to *Ctenocephalides felis* was unknown. Thus, the state of origin of the case was used to classify each cat as high risk or low risk of exposure to *C felis* as previously described ([@bib18]). Samples were categorized as being from areas with low (Alaska, Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming) or high flea prevalence (all other states). Age, flea risk, clinical manifestation, and *B henselae* titer were entered into a spreadsheet and analyzed by use of a commercially available statistical software package (SAS, SAS Institute, Cary, NC, Version 9.1). Relationships between *B henselae* serological status (positive or negative) and clinical presentations were first assessed by Fisher\'s exact test. Additionally, logistic regression was used to assess the influence of serological status, age and risk of flea exposure on clinical presentation. Relationships between *B henselae* titer magnitude and clinical manifestations were assessed by determining median titers for each group and evaluated with Wilcoxon\'s rank sum test. Significance was defined as *P*  \< 0.05.

Results {#sec3}
=======

Group 1 consisted of 145 cats; seizures were reported for 63 cats and other neurological signs were reported for 82 cats. Of the cats, 44 were from low flea risk states (Colorado and Montana) and 101 were from high flea risk states (Arkansas, California, Florida, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Mississippi, Missouri, Nebraska, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Texas, Virginia, Washington, and Wisconsin). There was no difference in *B henselae* seroprevalence rates (*P*  = 0.0662) between cats with seizures (37 of 63 cats; 59%) and cats with other neurological diseases (35 of 82 cats; 43%). When the analysis was expanded to include age and risk of flea exposure by logistic regression, neither of these additional factors were significant (*P*  \> 0.05) and the effect of seropositivity was still not significant (*P*  = 0.0707). However, the median titers of cats with seizures (median 1:64; titer range 0--1:1024) were significantly greater (*P*  = 0.0227) than cats with other neurological signs (median 0; titer range 0--1:2048).

Group 2 (clinically ill cats without neurological disease) consisted of 163 cats. Of the cats, 67 were from low flea risk states (Colorado, Montana, and New Mexico) and 96 were from high flea risk states (California, Florida, Iowa, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Texas, Washington, and Wisconsin). In the first evaluation, group 2 cats had a greater seropositive rate than group 1 cats ( [Table 1](#tbl1){ref-type="table"}; *P*  = 0.0153). When the analysis was expanded to include age and risk of flea exposure by logistic regression, neither of these additional factors influenced the seropositive rate within group (*P*  \> 0.05) and the effect of group was still significant (*P*  = 0.0026). Median titers of cats were not significantly different (*P*  = 0.5682) between group 1 (median 0; titer range 0--1:2048) and group 2 (median 1:64; titer range 0--1:4096).Table 1Relationships between *Bartonella henselae* seroprevalence rates between cats with and without neurological diseaseSeroprevalence \# positive (%)*P* value[∗](#tblfn1){ref-type="table-fn"}Group 1 (*n* = 145)72 (49.7%)Group 2 (*n* = 163)104 (63.8%)0.0153Group 3 (*n* = 97)68 (70.1%)0.0022[^2][^3]

Group 3 (healthy cats) consisted of 97 cats. Of the cats, 53 were from low flea risk states (Colorado and Utah) and 44 were from high flea risk states (California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Louisiana, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, New Hampshire, New Jersey, New York, North Carolina, Ohio, Tennessee, Texas, and Wisconsin). When group 1 cats were compared to group 3 cats, group was included in the statistical model as the covariate instead of neurological manifestations. In the first evaluation, group 3 cats had a greater seropositive rate than group 1 cats ([Table 1](#tbl1){ref-type="table"}; *P*  = 0.0022). When the analysis was expanded to include age and risk of flea exposure (logistic regression), neither of these additional factors influenced the seropositive rate within group (*P*  \> 0.05) and the effect of group was still significant (*P*  = 0.0001). Median titers of cats were significantly different (*P*  = 0.0411) between groups with group 3 titers (median 64; titer range 0--1:8192) being greater than those for group 1 (median 0; titer range 0--1:2048).

Discussion {#sec4}
==========

Samples for this retrospective study were submitted by a variety of veterinarians that included general practitioners and veterinary neurologists and the complete medical record was not available for most cases. Thus, one of the major limitations to this study is the lack of a consistent neurological examination between cases. And so there is the possibility that some cats in group 1 did not have neurological disease and some cats in group 2 had neurological disease which potentially could have influenced the results. Encephalopathy, with several classical manifestations including headaches, confusion, excitability, combative behavior, tonic-clonic seizures, status epilepticus and coma ([@bib4], [@bib5], [@bib1], [@bib44]) is the most common neurological complication of CSD in man, occurring in 2--3% of affected patients ([@bib4]). Because these different clinical signs of encephalopathy can be hard to categorize in cats, we felt subdivision of the cases into categories other than seizures or other neurological manifestations would be potentially inaccurate. In future prospective studies, cases should be solicited from a limited number of veterinary neurologists to allow for more accurate case classification which may aid in detection of clinical disease associations.

The *B henselae* seroprevalence rates in this study are similar to those reported in other studies ([@bib18], [@bib12], [@bib31], [@bib16]). Because some experimentally inoculated cats develop neurological disease after inoculation with *B henselae*, it is likely the same syndromes occur in client-owned cats as well ([@bib19], [@bib33], [@bib28]). However, in this study, the prevalence of *Bartonella* species antibodies in serum of cats with neurological manifestations of disease (group 1) was less than a group of clinically ill cats without neurological signs (group 2) and a group of healthy cats (group 3). In another study of sick cats in North Carolina, prevalence of *B henselae* antibodies was similar between cats with and without neurological dysfunction ([@bib3]). Results of these studies emphasize how difficult it can be to diagnose clinical bartonellosis in individuals based on the result of a single serological test result.

Flea exposure and age have both been associated with risk of exposure to *B henselae* but these variables did not affect the statistical outcomes in our study ([@bib12], [@bib16]). Because we could not accurately determine the flea risk for individual cats of this study we had to assign flea risk by state ([@bib18]). It would have been optimal to have exact flea history instead of just state history as flea prevalence can vary between and within states.

It is unknown why some cats develop clinical bartonellosis and others do not. There are different variants and strains of *B henselae* which may have different pathogenic potentials ([@bib33], [@bib28], [@bib9], [@bib10]). In addition, bartonellosis in people relates to the host response to the pathogen ([@bib36]). In the study described here, additional clinical information was not available. Future prospective studies of potential neurological bartonellosis in cats should include a more detailed clinical history and diagnostic workup.

Antibodies that bind to *B henselae* antigens used in serological assays may not indicate exposure or infection with *B henselae*, which also may affect the diagnosis of bartonellosis. For example, antigens from culture derived *B henselae* were used in the ELISA used in this study. However, in titration experiments, sera from a number of cats currently polymerase chain reaction (PCR) assay positive for *B clarridgeiae* DNA but not *B henselae* DNA in blood were positive in the ELISA described herein. To our knowledge, *B clarridgeiae* has not been associated with clinical illness in cats. It is now apparent that some humans with suspected *B henselae* associated illness were actually infected by *B koehlerae* ([@bib2]). In the future, prospective studies evaluating for potential disease associations with *Bartonella* species should use techniques like PCR assay or culture with subsequent genotyping to allow for more stringent organism identification ([@bib23], [@bib38], [@bib11]).

Predictive value of the magnitude of serum antibody titers has been assessed in several human studies with variable results ([@bib13], [@bib37]). For example, *B henselae* antibody titers of varying magnitudes were commonly detected in healthy children in Italy ([@bib25]), healthy veterinarians in Japan ([@bib20]), and people with CSD ([@bib13]). In the study described here, median *Bartonella* species antibody titers were greater in cats with seizures than in cats with other neurological disease. However, the median *Bartonella* species antibody titer was also greater in healthy cats than cats with seizures. These results suggest that titer magnitude in cats cannot be used alone to document clinical disease associated with *Bartonella* species infection.

In summary, we believe the results of this study document that presence of serum antibodies alone cannot be used to document clinical neurological bartonellosis in cats and that improved diagnostic tests are needed. Cerebrospinal fluid analysis findings in people with neurological CSD are variable and non-specific ([@bib4], [@bib5], [@bib30]). However, detection of *Bartonella* species antibody production by ocular tissues and microbial DNA has been amplified from aqueous humor of cats with uveitis ([@bib22]). Use of these techniques with cerebrospinal fluid of cats may prove to be of benefit in the diagnosis of neurological bartonellosis.
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[^1]: Dr Radecki is a statistical consultant in Fort Collins.

[^2]: Group 1 consisted of cats with neurological disease, group 2 consisted of clinically ill cats without neurological disease, and group 3 consisted of healthy cats.

[^3]: Compared to group 1 by Fisher\'s exact test in the initial analysis. There was no significant effect of age or flea risk on results by logistic regression.
